Development of a new anti-cancer therapy by bio-drug delivery system with somatic stem cells

Research Project

Project/Area Number	25430160
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Tumor therapeutics
Research Institution	Osaka Medical College
Principal Investigator	II MASAAKI 大阪医科大学, 実験動物部門, 講師 (10442922)
Co-Investigator(Renkei-kenkyūsha)	TABATA YASUHIKO 京都大学, 再生組織構築研究部門生体材料学分野, 教授 (50211371)
Research Collaborator	AOKI MASAHIKO
Project Period (FY)	2013-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywords	がん治療 / 脂肪幹細胞 / DDS / 抗がん剤 / 膵癌 / 癌治療 / ドラッグデリバリー / 体性幹細胞
Outline of Final Research Achievements	We made a biodegradable anti-cancer drug (Pirarubicin: Pir) conjugated PLGA nanoparticle, and loaded them into human adipose-derived mesenchymal stem cells generating a cell-complex (PirNP-hAdSC). The in vitro experiment in which human pancreatic cancer cells (KP1N) and PirNP-hAdSCs were co-cultured exhibited significant inhibition of proliferation and migration and promotion of apoptosis in KP1N cells. We will evaluate tumor growth in KP1N bearing immunodeficient mice after intravenous administration of 1) PBS, 2) PirNP alone, 3) hAdSCs alone, and 4) PirNP-hAdSCs upto 4 weeks after KP1N transplantation with one week interval.